Positive impactIPO
Molbio IPO Day 2: GMP hits at 17% listing gains. Should you bid?
Economic Times 1 hr ago·11 Aug 2026, 4:03 am
Molbio Diagnostics' IPO is in its second day of bidding, and the market sentiment is turning positive. The grey market premium (GMP), which indicates the price investors expect the stock to list at, has climbed to 17%. This suggests that the listing gains could be significant if the stock opens at a premium over the issue price.
The IPO has already seen strong demand, with subscriptions reaching 83% on the first day. Retail investors have been particularly active, subscribing to 77% of their allotted quota. This high level of interest from the public indicates that the stock is viewed favorably by the retail segment.
Investors should keep an eye on the final subscription numbers and the GMP as the bidding period concludes. The final listing price will be determined on the basis of these factors. It is important to note that the grey market premium is not a guarantee of listing gains.
Key takeaways
- Category: IPO.
- AI reads the tone as positive (potentially bullish) for the stock.
Why it matters
A routine update. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.
